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Abstract
The mTOR inhibitor rapamycin ameliorates the clinical and
biochemical phenotype of mouse, worm, and cellular models of
mitochondrial disease, via an unclear mechanism. Here, we
show that prolonged rapamycin treatment improved motor
endurance, corrected morphological abnormalities of muscle,
and increased cytochrome c oxidase (COX) activity of a muscle-
specific Cox15 knockout mouse (Cox15sm/sm). Rapamycin treat-
ment restored autophagic flux, which was impaired in naïve
Cox15sm/sm muscle, and reduced the number of damaged mito-
chondria, which accumulated in untreated Cox15sm/sm mice.
Conversely, rilmenidine, an mTORC1-independent autophagy
inducer, was ineffective on the myopathic features of
Cox15sm/sm animals. This stark difference supports the idea that
inhibition of mTORC1 by rapamycin has a key role in the
improvement of the mitochondrial function in Cox15sm/sm
muscle. In contrast to rilmenidine, rapamycin treatment also
activated lysosomal biogenesis in muscle. This effect was asso-
ciated with increased nuclear localization of TFEB, a master
regulator of lysosomal biogenesis, which is inhibited by
mTORC1-dependent phosphorylation. We propose that the coor-
dinated activation of autophagic flux and lysosomal biogenesis
contribute to the effective clearance of dysfunctional mitochon-
dria by rapamycin.
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Introduction
Mitochondrial diseases are genetically and clinically heterogeneous
conditions characterized by defects of oxidative phosphorylation
(OXPHOS). Mutations in either nuclear or mitochondrial DNA
(mtDNA) genes can lead to mitochondrial dysfunction, which may
result in a wide array of clinical manifestations, ranging from rela-
tively benign, late-onset (encephalo)myopathies to extremely
severe, early-onset encephalopathies, cardiomyopathies, or multi-
system failure (Gorman et al, 2016). No cure or effective therapy is
currently available for mitochondrial diseases, although recent stud-
ies showed potential benefit of several approaches, at least in
preclinical in vivo models (Chinnery, 2015; Viscomi et al, 2015;
Viscomi, 2016). Given the clinical, biochemical, and genetic hetero-
geneity of mitochondrial diseases, and the rarity of the single
syndromes, therapeutic approaches with wide applicability would
be preferable, but this is a difficult task to achieve (Viscomi et al,
2015).
Rapamycin is a widely used inhibitor of mechanistic target of
rapamycin (mTOR), a cytosolic Ser/Thr kinase belonging to the
phosphatidylinositol kinase-related family of protein kinases, with
central roles in several cellular processes, including protein transla-
tion, immune response, nucleotide and lipid synthesis, glucose
metabolism, autophagy, and lysosomal biogenesis (Saxton & Saba-
tini, 2017). In the cytosol, mTOR forms two complexes, mTORC1
and mTORC2. The main function of mTORC1 is the activation of
anabolic processes, whereas mTORC2 has major roles in regulating
the structure of cytoskeleton and cell proliferation. Rapamycin acts
by forming a ternary complex with the peptidyl-prolyl-isomerase
FK506-binding protein 12 (FKBP12), a component of mTORC1 (Sax-
ton & Sabatini, 2017), and the FKBP12-rapamycin binding (FRB)
domain of mTOR. This prevents substrate recruitment at the active
site (Yang et al, 2013), leading to a block of mTORC1, and a switch
of cell metabolism toward catabolic processes. By contrast,
mTORC2 is insensitive to acute rapamycin exposure, although
prolonged treatment does also abrogate mTORC2 signaling, as
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rapamycin-bound mTOR cannot be incorporated into new mTORC2
complexes (Saxton & Sabatini, 2017). One of the consequences of
rapamycin inhibition of mTORC1 is the activation of (macro)au-
tophagy. This is a highly conserved process conveying substrates,
including protein aggregates, infective agents and organelles, to the
lysosome for degradation. Targets for degradation are first enclosed
into specialized, double-membrane structures called autophago-
somes, whose formation (phagophore), elongation, and closure are
controlled by autophagy-related (ATG) proteins (Bento et al, 2016;
Menzies et al, 2017). Autophagosomes are eventually fused with
lysosomes to generate autophagolysosomes that carry out the diges-
tion of the substrates. mTOR-dependent and mTOR-independent
pathways regulate autophagy. The former involves the activation of
class I phosphoinositide 3-kinase (PI3K), protein kinase B (PKB),
and mTORC1, which blocks autophagy by phosphorylating ULK1, a
kinase driving autophagosome formation, thus preventing its activa-
tion by AMPK. The mTOR-independent pathway involves numerous
targets and can include the activation of the cAMP-dependent
exchange protein (EPAC), the small G protein RAP2B, and phospho-
lipase C epsilon (PLCe). PLCe increases the production of inositol-
1,4,5-triphosphate and, as a consequence, the release of calcium
from the endoplasmic reticulum. This in turn leads to the activation
of the calcium-dependent phosphatase calpain, which inhibits
autophagy.
Rapamycin has recently been reported as beneficial in mouse
and cellular models of mitochondrial disease (Johnson et al, 2013,
2015; Zheng et al, 2016; Felici et al, 2017; Khan et al, 2017; Sieg-
mund et al, 2017). The mechanisms underlying these effects are
poorly understood. Although activation of autophagy upon
rapamycin treatment has been reported in some of these studies
(Johnson et al, 2015; Khan et al, 2017), others failed to detect it
(Felici et al, 2017; Siegmund et al, 2017), but all were based on the
measurement of autophagy markers at the steady state, whereas
autophagic flux was not investigated in detail.
Here, we used the Cox15sm/sm mouse (Viscomi et al, 2011; Civi-
letto et al, 2015), in order to investigate how mTORC1 signaling
and autophagy flux are regulated in a skeletal muscle-restricted
mitochondrial disease model, and whether and how rapamycin can
modify these mechanisms and impact on the myopathic phenotype.
Furthermore, we compared the effects of rapamycin, an mTORC1-
dependent autophagy activator, with those of rilmenidine, a
pro-autophagic drug acting through the mTORC1-independent
pathway.
Results
Rapamycin improves motor endurance, muscle morphology, and
mitochondrial structure of Cox15sm/sm mice
Cox15sm/sm mice lack the gene encoding Cox15 in skeletal muscle
(Viscomi et al, 2011; Civiletto et al, 2015). Cox15 oxidizes the C8-
methyl group of heme O during the biosynthesis of the cyto-
chrome c oxidase (cIV, COX)-specific heme A. Cox15sm/sm mice
are characterized by profound COX deficiency, leading to severe
myopathy. We administered rapamycin intraperitoneally (i.p.)
(8 mg/kg/day) to both Cox15sm/sm and wild-type (WT) weaning
littermates (21 days after birth), for 4 weeks. Rapamycin induced
a mild, non-significant growth retardation in both treated WT and
Cox15sm/sm animals (not shown), and a significant improvement
of the motor performance, measured by standard treadmill test,
from week 2 to the end of the treatment (Fig 1A). Histological
and histochemical analysis of skeletal muscle revealed a consistent
amelioration of pathology in rapamycin-treated versus vehicle-
treated (naı¨ve) Cox15sm/sm animals (Fig 1B). Hematoxylin and
eosin (H&E) staining showed a significant increase in the cross-
sectional area (CSA) of the muscle fibers (Fig 1C) and a drastic
reduction in centralized nuclei (Fig 1D) in rapamycin-treated
versus naı¨ve Cox15sm/sm mice. PAS staining also revealed an accu-
mulation of glycogen in skeletal muscle of naı¨ve Cox15sm/sm mice,
which was further and significantly increased in treated
Cox15sm/sm animals (Fig 1E). COX histochemistry in skeletal
muscle showed significantly increased COX reaction (Fig 1F), and
a parallel reduction of SDH reaction, another index of mitochon-
drial proliferation, in treated versus naı¨ve Cox15sm/sm animals
(Fig 1G). Spectrophotometric measurements in muscle homoge-
nates (Fig 2A) showed that citrate synthase (CS) activity, an index
of mitochondrial mass, was significantly increased in naı¨ve
Cox15sm/sm, and returned to normal values in muscle homogenates
of rapamycin-treated Cox15sm/sm mice. The specific activity of
COX (cIV) was significantly lower in Cox15sm/sm samples and
remained unchanged under rapamycin treatment. As a conse-
quence, cIV/CS activity increased in treated versus naı¨ve
Cox15sm/sm (Fig 2A). The protein levels of NDUFA9, a cI subunit;
UQCRC2, a cIII subunit; and ATP5A, a cV subunit, were markedly
increased in naı¨ve Cox15sm/sm versus WT and were reduced to
WT levels upon rapamycin treatment (Fig 2B), while cII subunit
SDHA was unchanged in untreated Cox15sm/sm versus WT and
was slightly reduced after rapamycin treatment. cIV subunit COX4
was profoundly reduced in both rapamycin-treated and untreated
Cox15sm/sm mice, as expected given the role of COX15 in cIV
biogenesis. No differences were detected between treated versus
naı¨ve WT animals. One-dimension blue native gel electrophoresis
(1D-BNGE) in-gel activity and immunovisualization confirmed a
slight increase in COX reaction and amount of fully assembled cIV
in rapamycin-treated versus naı¨ve Cox15sm/sm muscle samples
(Fig 2C and D), while no differences were detected in complex I
(not shown). Pyruvate/glutamate/malate (not shown)- and succi-
nate-stimulated oxygen consumption (Fig 2E), which was signifi-
cantly reduced in Cox15sm/sm versus WT mitochondria isolated
from skeletal muscles, again significantly increased in treated
Cox15sm/sm animals (Fig 2E).
Upon rapamycin treatment, mtDNA copy number in skeletal
muscle, which was increased in naı¨ve Cox15sm/sm mice, returned to
levels comparable to WT (Fig 2F).
Modified Gomori trichrome staining showed a remarkable
decrease in the reddish hue of the muscle fibers, indicating reduced
mitochondrial proliferation in treated versus naı¨ve Cox15sm/sm mice.
A decrease in “blue fibers”, i.e., fibers completely devoid of COX
reaction, was also detected in treated versus naı¨ve Cox15sm/sm
(Appendix Fig S1).
Ultrastructurally, while a huge number of giant mitochondria
with big vacuoles and disrupted cristae were detected in naı¨ve
Cox15sm/sm muscle fibers, damaged mitochondria were significantly
decreased in the rapamycin-treated Cox15sm/sm samples (Fig 3 and
Appendix Fig S2). Quantitative EM analysis confirmed a significant
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decrease in damaged mitochondria upon rapamycin treatment,
whereas the number of autophaged mitochondria, i.e., organelles
engulfed in autophagic vacuoles, was comparable in rapamycin-
treated versus naı¨ve Cox15sm/sm (Appendix Fig S2). No differences
were observed in the number of mitochondria with normal
structure.
Altogether, these data indicate that rapamycin treatment remark-
ably ameliorates the myopathic phenotype, possibly through
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Figure 1. Rapamycin treatment improves the myopathic phenotype of Cox15sm/sm mice.
A Treadmill analysis (n = 8/group). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue: rapamycin-treated Cox15sm/sm. Error bars
represent SEM. The asterisks represent the significance levels calculated by unpaired, two-tailed Student’s t-test: ***P = 0.005 (week 2); ***P = 0.0007 (week 3); and
****P < 0.0001 (week 4). Only P-values for rapamycin-treated versus untreated Cox15sm/sm mice are shown.
B Histological and histochemical characterization of skeletal muscle in rapamycin-treated and untreated Cox15sm/sm and WT mice. H&E: hematoxylin and eosin; PAS:
periodic acid–Schiff reaction; COX: cytochrome c oxidase; SDH: succinate dehydrogenase. Scale bars correspond to 50 lm.
C Analysis of the cross-sectional area of muscle fibers in the different genotypes (n = 3/group). Black: untreated WT; gray: rapamycin-treated WT; red: untreated
Cox15sm/sm; blue: rapamycin-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s
post hoc multiple comparison test: ***P = 0.001; ***P = 0.006; and ****P < 0.0001.
D Analysis of the number of centralized nuclei in muscle fibers (n = 3/group). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue:
rapamycin-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple
comparison test: **P = 0.0018 (Cox15sm/sm versus WT), **P = 0.0052 (Cox15sm/sm-rapamycin versus Cox15sm/sm).
E Analysis of PAS-reaction intensity in muscle fibers (n = 4/group). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue: rapamycin-treated
Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple comparison test:
*P = 0.0293 (WT versus Cox15sm/sm) and *P = 0.0150 (Cox15sm/sm versus Cox15sm/sm+rapamycin).
F Analysis of COX-reaction intensity in muscle fibers (n = 3). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue: rapamycin-treated
Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple comparison test:
****P < 0.0001; **P = 0.0031.
G Analysis of SDH-reaction intensity in muscle fibers (n = 3). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue: rapamycin-treated
Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple comparison test:
*P = 0.0199, **P = 0.0091.
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◀ Figure 2. Rapamycin improves the biochemical phenotype of Cox15sm/sm skeletal muscles.A Spectrophotometric activities of the respiratory chain (n = 4–5/group). CS: citrate synthase; cIV: complex IV. Black: untreated WT; gray: rapamycin-treated WT; red:
untreated Cox15sm/sm; blue: rapamycin-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by two-way ANOVA
with Tukey’s correction: ****P < 0.0001 (CS: WT versus Cox15sm/sm), ***P = 0.0010 (CS: Cox15sm/sm versus Cox15sm/sm rapamycin), ***P = 0.005 (cIV: Cox15sm/sm versus
WT), ****P < 0.0001 (cIV/CS: WT versus Cox15sm/sm), **P = 0.0060 (cIV/CS: Cox15sm/sm rapamycin versus Cox15sm/sm).
B Western blot immunovisualization of subunits of the respiratory complexes. Note the increased protein levels in Cox15sm/sm versus WT samples, which are reduced to
normal levels upon rapamycin treatment. Additional samples were run on a separate gel (not shown).
C BNGE in-gel activity for cIV. Sc: supercomplexes. Note that the COX reaction is slightly increased in rapamycin-treated versus untreated Cox15sm/sm samples.
D Immunoblot of 1D-BNGE using an anti-cIV antibody (COX1). Note that COX amount is slightly increased in rapamycin-treated versus untreated Cox15sm/sm muscles.
SDHB was used as a loading control.
E State III (succinate-driven) oxygen consumption (n = 3/group). Error bars represent SEM. The asterisks represent the significance levels calculated by unpaired,
two-tailed Student’s t-test: **P = 0.0016 (WT versus Cox15sm/sm); *P = 0.047 (Cox15sm/sm versus Cox15sm/sm+rapamycin).
F Analysis of mtDNA amount (n = 9/group). Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s
correction: **P = 0.0020; *P = 0.0296.
Figure 3. Rapamycin improves mitochondrial ultrastructure in Cox15sm/sm mice.
Note the accumulation of profoundly altered mitochondria in Cox15sm/smmuscles (white arrows), possibly as a result of partially digested organelles within endolysosomes.
Black arrows indicate examples of normal mitochondria. In rapamycin-treated Cox15sm/sm animals, only a few of these structures are present, which can be detected also in
rapamycin-treated WT samples. The scale bar corresponds to 1,136 nm (4,400×).
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selective elimination of dysfunctional mitochondria in Cox15sm/sm
muscles.
Activation of autophagy via mTOR-dependent but not
mTOR-independent pathway ameliorates the phenotype of
Cox15sm/sm mice
We then investigated autophagy in the skeletal muscle of rapa-
mycin- and vehicle-treated naı¨ve Cox15sm/sm and WT littermates
(Fig 4A and B). The phosphorylation of S6 (P-S6), a ribosomal
protein which is a downstream target of mTORC1, was compara-
ble in naı¨ve WT versus Cox15sm/sm muscles, but was clearly
reduced in both genotypes upon rapamycin treatment, demon-
strating that rapamycin was able to effectively inhibit mTORC1
in vivo. Total S6, which was increased in naı¨ve Cox15sm/sm
versus WT muscles, returned to control levels by rapamycin
treatment (Fig 4A and B). Since P-S6 levels reflect the protein
translation rate, the reduced P-S6 levels we observed in rapa-
mycin-treated animals suggest a reduction in protein translation,
as expected in case of mTORC1 inhibition. P62, an autophagy
substrate, was increased in naı¨ve Cox15sm/sm versus WT samples
and normalized by rapamycin treatment (Fig 4A and B). Like-
wise, LC3-II, a marker of autophagosomes, accumulated in naı¨ve
Cox15sm/sm samples and remained higher than in controls after
rapamycin treatment (Fig 4A and B). Since the accumulation of
LC3-II can be due to either an increase or a block of autophagy,
we assessed autophagic flux in vivo by exposing both rapamycin-
treated and naı¨ve animals to colchicine, a blocker of lysosomal
fusion with autophagosomes (Fig 4C and Appendix Fig S3). In
basal conditions, Cox15sm/sm muscles displayed significantly
higher LC3-II levels than WT. Colchicine increased LC3-II in WT
but not in Cox15sm/sm muscles, suggesting a block of the
autophagic flux in the latter. Rapamycin alone did not change
LC3-II levels in either WT or Cox15sm/sm samples. However, the
combined exposure to rapamycin and colchicine significantly
increased LC3-II levels in Cox15sm/sm muscles, clearly indicating
that rapamycin treatment was associated with an increase in the
autophagic flux revealed by the addition of colchicine.
To investigate whether the mitophagy pathway could be
involved in the clearance of dysfunctional mitochondria, we investi-
gated the levels of PINK1 and Parkin in skeletal muscle-isolated
mitochondria from rapamycin-treated and untreated mice of both
genotypes. PINK1 clearly accumulated in mitochondria from
Cox15sm/sm versus WT mice (Appendix Fig S4), suggesting a
reduced membrane potential in Cox15sm/sm mitochondria, as we
recently reported (Dogan et al, 2018). Parkin, which was unde-
tectable in WT mitochondria irrespective of the treatment, was
recruited to Cox15sm/sm mitochondria (Appendix Fig S4). As
observed for other mitochondrial proteins, PINK1 was significantly
reduced in rapamycin-treated versus untreated Cox15sm/sm muscle
mitochondria (Appendix Fig S4), as a consequence of the increased
autophagic flux. Mitochondrial Parkin showed a similar trend
although the results displayed higher variability.
These results suggest that PINK1/Parkin-dependent mitophagy is
activated in Cox15sm/sm muscles, but is unable to efficiently clear
damaged mitochondria. In contrast, rapamycin, by restoring the
autophagic flux, significantly increased the elimination of dysfunc-
tional mitochondria in the mutant mice.
To further investigate the role of autophagy in the rapamycin-
mediated amelioration of the Cox15sm/sm phenotype, we used
rilmenidine, an agonist of imidazoline-1 receptor which regulates
cAMP levels and acts as an mTOR-independent autophagy
inducer.
Although rilmenidine increased the autophagic flux (Fig 5A), it
had no effect on the motor performance of Cox15sm/sm mice
(Fig 5B), and failed to improve muscle morphology (Fig 5C–E).
Ultrastructurally, rilmenidine was ineffective to significantly
reduce the number of damaged mitochondria (Appendix Figs S2 and
S5) and led to a significant increase in mitochondria-containing
autophagic vacuoles, compared to naı¨ve and rapamycin-treated
Cox15sm/sm muscles (Appendix Fig S2). These results indicate that
autophagy is not the only factor responsible for the rapamycin-
mediated effect in Cox15sm/sm mice.
Rapamycin induces lysosomal biogenesis in Cox15sm/sm
skeletal muscle
Transcription factor EB (TFEB) is a master regulator of lysosomal
biogenesis and autophagy. In its phosphorylated, inactive form,
TFEB localizes to the cytosol, but upon dephosphorylation by calci-
neurin, it translocates to the nucleus where it increases the tran-
scription of autophagy- and lysosome-related genes. Importantly,
TFEB is a direct target of mTORC1, which inactivates it by phospho-
rylation. The link between TFEB and mTORC1 prompted us to
◀ Figure 4. Rapamycin induces autophagy in Cox15sm/sm muscles.A Representative Western blot of autophagy markers at steady state in skeletal muscle. GAPDH was used as a loading control.
B Densitometric analysis of immunoblots similar to that shown in (A) (n = 4/group). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue:
rapamycin-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple
comparison test: **P = 0.0068 (LC3-II WT versus Cox15sm/sm), **P = 0.0063 (P62 WT versus Cox15sm/sm), *P = 0.025 (P62 Cox15sm/sm versus Cox15sm/sm+rapamycin),
**P = 0.0098 (S6 WT versus Cox15sm/sm), *P = 0.034 (P-S6 WT versus WT+rapamycin), ***P = 0.0002 (P-S6 Cox15sm/sm versus Cox15sm/sm+rapamycin), *P = 0.014
(P-S6/S6 WT versus WT+rapamycin), ***P = 0.0007 (P-S6/S6 Cox15sm/sm versus Cox15sm/sm+rapamycin).
C Analysis of the autophagic flux (n = 3/group). Upper panel: representative Western blot of Cox15sm/sm and WT muscles treated with colchicine, rapamycin, or
rapamycin plus colchicine. Note that LC3-II was increased in Cox15sm/sm versus WT samples. Colchicine did not increase LC3-II levels, suggesting a block in the
autophagic flux; rapamycin plus colchicine-treated Cox15sm/sm mice showed higher levels of LC3-II, suggesting that rapamycin increased the autophagic flux in
Cox15sm/sm muscles. Black: WT; dark gray: colchicine-treated WT; middle gray: rapamycin-treated WT; light gray: colchicine plus rapamycin-treated mice; red:
untreated Cox15sm/sm; orange: colchicine-treated; blue: rapamycin-treated Cox15sm/sm; purple: colchicine plus rapamycin-treated Cox15sm/sm. Error bars represent SEM.
The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple comparison test: **P = 0.0049 (WT versus
WT+colchicine), **P = 0.0046 (WT+rapamycin versus WT+rapamycin+colchicine), *P = 0.0225 (WT versus Cox15sm/sm), **P = 0.0057 (Cox15sm/sm colchicine versus
Cox15sm/sm+rapamycin+colchicine), ***P = 0.0003 (Cox15sm/sm rapamycin versus Cox15sm/sm+rapamycin+colchicine).
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investigate TFEB localization upon rapamycin treatment.
Immunofluorescence (IF) staining by an anti-TFEB antibody showed
a significant increase in the number of TFEB-positive nuclei in rapa-
mycin-treated Cox15sm/sm muscle compared to WT (Fig 6A and B).
Notably, rilmenidine did not induce TFEB translocation to the
nucleus.
In order to investigate whether increased nuclear localization of
TFEB was accompanied by increased lysosomal biogenesis, we
measured LAMP1 transcript, LAMP1-positive vesicles, and cathepsin
L activity in Cox15sm/sm and WT animals. Rapamycin-treated mice
of both genotypes showed significantly increased LAMP1 transcript
levels (Fig 7A). IF with an anti-LAMP1 antibody (Fig 7B) showed a
significantly higher number of lysosomes in naı¨ve Cox15sm/sm
compared to untreated and treated WT muscles (Fig 7B and C).
Rapamycin further increased significantly the number of lysosomes
in Cox15sm/sm samples (Fig 7B and C). Contrariwise, rilmenidine
had no effect on LAMP1 staining (Fig 7B and C). No difference was
detected in size among the LAMP1-positive vesicles (Appendix Fig
S6). Finally, cathepsin L activity was significantly increased in rapa-
mycin-treated compared to untreated Cox15sm/sm muscle samples
(Fig 7D). These results suggest that sustained lysosomal biogenesis
is fundamental to support efficient elimination of damaged mito-
chondria by autophagy.
Discussion
A number of reports have recently provided evidence that the
mTORC1 inhibitor rapamycin is able to partially ameliorate the
phenotype of mitochondrial disease in vivo, e.g., mouse models and
patient-derived mutant cells. For instance, administration of rapa-
mycin by daily i.p. injections led to a remarkable prolongation of
the lifespan, delay of the neurological derangement, and reduction
of neuroinflammation in Ndufs4/ mice, a model of severe
complex I deficiency (Johnson et al, 2013). Post-onset oral adminis-
tration of rapamycin at the same dose previously used i.p. (8 mg/kg)
delayed the development of the encephalopathy in the Ndufs4/
mouse (Felici et al, 2017). Also, neurons derived from induced
pluripotent stem cells (iPSCs) from a patient with maternally
inherited Leigh syndrome (MILS), carrying a mutation in the MT-
ATP6 gene, showed reduced glutamate toxicity after rapamycin
treatment. This effect was accompanied by inhibition of protein
synthesis and, as a consequence, sparing of ATP (Zheng et al, 2016).
Reduced ATP consumption and proteotoxic stress and activation of
autophagy were shown to contribute to the clinical and biochemical
amelioration of several models of mitochondrial dysfunction, i.e.,
human cells, C. elegans, and mice (Peng et al, 2015). More recently,
rapamycin was shown to inhibit the integrated mitochondrial stress
response (ISRmt), a complex tissue-specific set of homeostatic path-
ways, involving transcriptional and metabolic adaptations as well as
induction of the mitochondrial unfolded protein response (Khan
et al, 2017). Finally, low-dose rapamycin was reported to prolong
the lifespan of a thymidine kinase 2 (Tk2) knock-in mouse (Sieg-
mund et al, 2017). Although this effect was not accompanied by
modifications of the molecular hallmarks of the disease, RNAseq and
metabolomics data suggested significant changes in amino acid,
carbohydrate, and fatty acid metabolism in liver, with little effect on
the brain.
Nevertheless, a general consensus on the mechanisms underly-
ing the effects of rapamycin on primary mitochondrial dysfunction
is still lacking. Notably, the contribution of autophagy was not thor-
oughly addressed in these works.
Here, we have shown that rapamycin-induced inhibition of
mTORC1-dependent pathways plays a critical role in improving the
clinical phenotype of a mouse model characterized by severe mito-
chondrial myopathy. While mTOR signaling was not significantly
changed in naı¨ve Cox15sm/sm versus WT mice, autophagy flux was
reduced in Cox15sm/sm individuals, as demonstrated by increased
levels of P62 and unchanged LC3-II levels by colchicine. This block
was significantly overcome by the administration of either rapa-
mycin or rilmenidine. However, the striking difference of the clinical
and biochemical phenotypes by rapamycin versus rilmenidine
suggests that autophagy induction is not sufficient to achieve the
therapeutic effects and must be supported by the coordinated
increase in lysosomal biogenesis to carry out the selective clearance
of dysfunctional mitochondria. Although rapamycin seems to be a
weak regulator of TFEB in cells (Settembre et al, 2012), the rela-
tively prolonged treatment carried out in our experiments may have
◀ Figure 5. Rilmenidine induces autophagic flux, but does not improve the phenotype of Cox15sm/sm mice.A Analysis of the autophagic flux (n = 4/group). Upper panel: representative Western blot of Cox15sm/sm and WT muscles treated with colchicine, rilmenidine, or
rilmenidine plus colchicine. Colchicine alone increased LC3-II in WT but not Cox15sm/sm mice; rilmenidine had no effect on WT LC3-II levels, but reduced them in
Cox15sm/sm mice. Rilmenidine plus colchicine increased LC3-II levels in both WT and Cox15sm/sm mice. Black: WT; dark gray: colchicine-treated WT; middle gray:
rapamycin-treated WT; light gray: colchicine plus rapamycin-treated mice; red: untreated Cox15sm/sm; orange: colchicine-treated; blue: rapamycin-treated Cox15sm/sm;
purple: colchicine plus rapamycin-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with
Tukey’s post hoc multiple comparison test: *P = 0.012 (WT versus WT+colchicine), **P = 0.0093 ((WT+rilmenidine versus WT+rilmenidine+colchicine), ***P = 0.0001
(WT versus Cox15sm/sm), **P = 0.0083 (Cox15sm/sm versus Cox15sm/sm+rilmenidine), *P = 0.0112 (Cox15sm/sm versus Cox15sm/sm+rilmenidine+colchicine), **** P < 0.0001
(Cox15sm/sm+rilmenidine versus Cox15sm/sm+rilmenidine+colchicine.
B Treadmill analysis (n = 4/group). Black: untreated WT; gray: rilmenidine-treated WT; red: untreated Cox15sm/sm; blue: rilmenidine-treated Cox15sm/sm. Error bars
represent SEM.
C Histological and histochemical characterization of skeletal muscle in rilmenidine-treated and untreated Cox15sm/sm and WT mice. H&E: hematoxylin and eosin; GT:
Gomori trichrome; PAS: periodic acid–Schiff reaction. The scale bar corresponds to 50 lm.
D Analysis of the cross-sectional area of muscle fibers in the different genotypes (n = 3/group). Black: untreated WT; gray: rilmenidine-treated WT; red: untreated
Cox15sm/sm; blue: rilmenidine-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s
post hoc multiple comparison test: ***P = 0.0002, ****P < 0.0001.
E Analysis of the number of centralized nuclei in muscle fibers (n = 3/group). Black: untreated WT; gray: rilmenidine-treated WT; red: untreated Cox15sm/sm; blue:
rilmenidine-treated Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple
comparison test: **P = 0.0091.
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induced more robust TFEB activation. An additional possibility is
that activation of transcription factor E3 (TFE3), another member of
the MiT/TFE family of transcription factors, with partially overlap-
ping activity with TFEB, may also contribute to increased lysosomal
biogenesis under rapamycin treatment.
Rapamycin was more effective in improving the autophagic
flux in Cox15sm/sm than in WT muscle. This is in agreement with
recently reported data supporting a link between mitochondrial
dysfunction and impairment of lysosomal activity (Demers-
Lamarche et al, 2016). Several mechanisms have been proposed
A
B
Figure 6. Rapamycin, but not rilmenidine, induces TFEB translocation to the nucleus.
A Anti-TFEB immunofluorescence on rapamycin- and rilmenidine-treated WT and Cox15sm/sm muscles versus untreated (UT) samples. CD11C (blue signal) indicates
inflammatory cells. The scale bars correspond to 30 lm.
B Quantification of the TFEB-positive nuclei (n = 3/group). Quantification was performed using Imaris spots surface excluding the CD11C-positive nuclei. Error bars
represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with Tukey’s post hoc multiple comparison test: *P = 0.0199 (WT versus
WT+rapamycin), *P = 0.0150 (Cox15sm/sm versus Cox15sm/sm+rapamycin), ***P = 0.0001.
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to contribute to the reciprocal impact between these organelles.
First, the molecular machineries involved in mitophagy,
mitochondrial-derived vesicles (MDVs), mitochondrial-derived
compartments (MDCs), and direct contact sites, mediate direct
cross-communication between the two organelles. In particular, it
has been recently shown that the lysosomal GTPase Rab7
controls not only lysosomal fission, but also mitochondrial fission
via interaction with TBC1D15, which is targeted to mitochondria
via interaction with Fis1, so that conditions affecting one
organelle can also impact on the other (Wong et al, 2018).
Second, mitochondrial dysfunction is a common finding in several
lysosomal storage disorders, and, similarly, mitochondrial
dysfunction may trigger lysosomal dysfunction (Plotegher &
Duchen, 2017). Third, the master regulator of lysosomal
biogenesis TFEB has been shown to regulate also mitochondrial
biogenesis and function (Mansueto et al, 2017).
A block of the autophagic flux may result in reduced clearance of
dysfunctional mitochondria in Cox15sm/sm muscle. This hypothesis
is supported by the accumulation of profoundly altered mitochon-
dria in Cox15sm/sm samples. The increase in mitochondria in autop-
hagic vesicles upon treatment with rilmenidine (Appendix Fig S2)
confirms that mitochondria are delivered to lysosomes (as expected
from the results on the autophagy flux experiment with colchicine),
but they are not efficiently degraded, unlike what occurs with
rapamycin.
Our results suggest that rapamycin induced the removal of
damaged mitochondria, as demonstrated by correction of muscle
morphology, reduction of mtDNA amount, normalization of CS
A
B
C
D
Figure 7. Rapamycin, but not rilmenidine, increases lysosomal biogenesis.
A Real-time PCR analysis of Lamp1 transcript (n = 3/group). Black: untreated WT; gray: rapamycin-treated WT; red: untreated Cox15sm/sm; blue: rapamycin-treated
Cox15sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by Student’s t-test: **P = 0.008, *P = 0.038.
B Anti-LAMP1 staining in rapamycin- and rilmenidine-treated WT and Cox15sm/sm muscles versus untreated (UT) samples. Rapamycin, but not rilmenidine, increases the
number of LAMP1-positive vesicles in Cox15sm/sm samples (inset). The scale bars correspond to 30 lm.
C Quantification of LAMP1-positive vesicles (n = 3/group). Error bars represent SEM. The asterisks represent the significance levels calculated by one-way ANOVA with
Tukey’s post hoc multiple comparison test: ****P < 0.0001.
D Cathepsin L specific activity (n = 3/group). Error bars represent SEM. The asterisks represent the significance levels calculated by Student’s t-test: *P = 0.0133.
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activity, and increased mitochondrial respiration. In addition, our
data on PINK1/Parkin indicate that rapamycin activates a selective
mitophagy pathway, which warrants future investigation.
In spite of the marked improvement in the muscle morphology
and mitochondrial ultrastructure, the improvement in motor perfor-
mance, albeit significant, is rather limited, and treated mice still
perform much less than the WT littermates. Several reasons may
explain this observation, including the relatively late age of the mice
at the start of treatment (weaning), and the intrinsic limitations of
our mouse model, which lacks an essential gene, so that the treat-
ment can only have a limited impact on the biochemical defect.
These effects were associated with both increased autophagic flux
and lysosomal biogenesis. Contrariwise, rilmenidine treatment,
which leads to activation of autophagy without the concurrent
increase in lysosome biogenesis, completely failed to improve the
clinical and morphological phenotype of Cox15sm/sm mouse muscles.
Likewise, rilmenidine failed to ameliorate the disease progression in
a SOD1 transgenic mouse model of amyotrophic lateral sclerosis
(Perera et al, 2017).
In conclusion, we provide solid evidence that rapamycin induces
substantial amelioration of mitochondrial function and ultrastruc-
ture, indicating efficient clearance of dysfunctional organelles by
parallel activation of both autophagic flux and lysosomal biogenesis in
skeletal muscle. Our results do not exclude that other mechanisms
can be involved in mediating rapamycin effects. The reduction in
phospho-S6 levels, clearly observed in the skeletal muscle of both
treated WT and Cox15sm/sm animals, indicates that translation is
indeed inhibited by rapamycin, and this may well contribute to the
overall effect, as previously suggested (Peng et al, 2015; Zheng
et al, 2016). Likewise, metabolic effects such as those reported by
others (Johnson et al, 2013; Khan et al, 2017; Siegmund et al, 2017)
are likely to have a role in the phenotypic amelioration of our mice.
However, we propose that the activation of the TFEB-dependent
transcriptional program, via rapamycin-dependent inhibition of the
mTORC1 kinase activity, significantly contributes to the overall
effect of rapamycin in ameliorating the phenotype of Cox15sm/sm
mice.
Notably, rapamycin seems to be beneficial in all the models of
mitochondrial disease so far analyzed, but its use in the treatment
of mitochondrial patients raises several concerns, mainly related to
side effects such as immunosuppression and glucose intolerance.
However, preliminary evidence in healthy elderly volunteers
showed that everolimus, a derivative of rapamycin, improved
immune response to influenza vaccination in elderly people (Man-
nick et al, 2014). Overall, our data encourage additional studies in
mice and humans to investigate the long-term effects and to test
safety, tolerability, and eventually efficacy of rapamycin and
rapalogs.
Materials and Methods
Reagents and materials
Antibodies anti-COX4, anti-UQCRC2, anti-NDUFA9, anti-ATP5A,
anti-SDHA were from Abcam (OXPHOS cocktail ab110412, dilution
1:2,000); anti-SDHB (ab14714, dilution 1:200) and anti-COX1
(ab14705, dilution 1:2,000) were from Abcam; anti-HSC70 was from
Santa Cruz (sc-7298, dilution 1:1,000); anti-GAPDH was from
Abcam (ab8245, dilution 1:40,000); anti-P62 was from Abnova
(H00008878-M01, dilution 1:1,000); anti-LC3-I/II was from Novus
Biologicals (NB100-2220, dilution 1:1,000); anti-LAMP1 was from
Cell Signaling (3243, dilution 1:1,000); anti-PINK1 was from Novus
(BC100-494, dilution 1:1,000); and anti-Parkin was from Abcam
(ab77924, dilution 1:500).
Animal work
All procedures were conducted under the 1986 UK Animals (Scien-
tific Procedures) Act and approved by Home Office license (PPL:
7538 and P6C97520A) and local ethical review. The mice were kept
on a C57Bl6/129Sv mixed background, and wild-type littermates
were used as controls. The animals were maintained in a tempera-
ture- and humidity-controlled animal care facility, with a 12-h light/
dark cycle and free access to water and food, and were sacrificed by
cervical dislocation.
Behavioral analysis
Treadmill analysis (Panlab, Barcelona, Spain) was performed as
described in Viscomi et al (2011). Briefly, motor exercise endurance
was assessed according to the number of falls in the motivational
air puff during a gradually accelerating program with speed initially
at 6.5 m/min and increasing by 0.5 m/min every 3 min. The test
was terminated by exhaustion, defined as > 10 falls/min into the
motivational air puff.
Oxygen consumption studies
Mouse muscles were homogenized in 0.075 M sucrose, 0.225 M
mannitol, 1 mM EGTA, 0.01% fatty acid-free BSA (pH 7.4), and
subtilisin 1 mg/g of muscle (Frezza et al, 2007). Mitochondria were
isolated by differential centrifugation and resuspended in 25 mM
sucrose, 75 mM sorbitol, 100 mM KCl, 0.05 mM EDTA, 5 mM
MgCl2, 10 mM Tris–HCl (pH 7.4), and 10 mM H3PO4, pH 7.4 (Fer-
nandez-Vizarra et al, 2002).
For oxygraphic measurements, 75–150 lg of mitochondrial
proteins was incubated in a buffer containing 225 mM sucrose,
75 mM mannitol, 10 mM Tris–HCl (pH 7.4), 10 mM KCl, 10 mM
KH2PO4, 5 mM MgCl2, and 1 mg/ml fatty acid-free BSA, pH 7.4.
Oxygen consumption was evaluated by high-resolution respirome-
try using an Oroboros O2k apparatus (Oroboros Instruments,
Austria), using the following substrate and inhibitor concentra-
tions: 5 mM succinate and 2 lM rotenone for cII-dependent
respiration; and 6 mM ascorbate and 300 lM TMPD and anti-
mycin A 0.25 lg/ml for cIV-dependent respiration. 100 lM ADP
was added to stimulate ATP-coupled oxygen consumption.
100 lM NaCN was added to completely inhibit respiration (Frezza
et al, 2007).
Blue native gel electrophoresis
For BNGE analysis, 250 lg of mitochondria isolated as described
above was resuspended in native PAGE buffer (Invitrogen),
protease inhibitors, and 4% digitonin and incubated for 1 h on
ice before centrifuging at 20,000 g at 4°C. 5% Coomassie G250
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was added to the supernatant. 30 lg was separated by 3–12%
gradient BNGE and either stained for in-gel activities or
electroblotted on PVDF membranes for immunodetection (Nijtmans
et al, 2002).
Morphological analysis
For histochemical analysis, tissues were frozen in liquid-nitrogen-
pre-cooled isopentane. Eight-micrometer-thick sections were stained
for COX and SDH, as described in Sciacco and Bonilla (1996). Analy-
sis of cross-sectional area and centralized nuclei and analysis was
performed on H&E-stained sections using ImageJ on four samples/
genotype (600 fibers/sample). For ultrastructural studies, muscle
samples were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4) at 4°C, post-fixed in 2% OsO4 in 0.1 M cacodylate
buffer (pH 7.4) for 1 h, dehydrated in a graded series of ethanol and
finally embedded in Epon resin. Thin sections were stained with
lead citrate and uranyl acetate and evaluated with a transmission
electron microscope (EM 109; Zeiss), as described in Cortese et al
(2014).
For SDH, COX, and PAS analysis, five images per sample (six
images for PAS) were acquired randomly in places of mixed-inten-
sity fibers keeping the same light intensity and exposure settings
using an Axio Observer Z1 with ApoTome 2 (Carl Zeiss Ltd.),
composed of a Zeiss 10× ApoPlan objective and an AxioCam ICc1
camera. Images were acquired using Zen Pro software and analyzed
with Fiji (Schindelin et al, 2012) (% of total area) keeping the same
threshold for all samples.
Immunofluorescence and imaging
For immunofluorescence, 8-lm frozen skeletal muscle sections
were fixed in 4% PFA for 10 min, washed in PBS, and then
incubated in 0.2% Triton in PBS for 15 min. After washing in
PBS, sections were incubated in blocking solution (5% normal
goat serum, 2% BSA, 1:40 M.O.M. blocking reagent in PBS) for
1 h at room temperature and then incubated with the primary
antibodies diluted in DAKO Antibody Diluent with Background
Reducing Components for 1 h at RT (1:1,000, anti-LAMP1,
#ab24170 from Abcam; 1:200, anti-TFEB, #A303-673A, from
Bethyl Laboratories; 1:200, Alexa Fluor 647 anti-mouse CD11c,
#117312, from BioLegend). Slides were washed in PBS for 15 min
and then incubated for 1 h at RT with Alexa Fluor secondary
antibodies (1:300 in DAKO Antibody Diluent with Background
Reducing Components). Sections were washed in PBS and
mounted with ProLong Diamond Antifade Mountant with DAPI
(Invitrogen). The images were acquired using a Dragonfly Spin-
ning Disk imaging system (Andor Technologies Ltd.), composed
of a Nikon Ti-E microscope, Nikon Apochromat 20×0.75 (for
TFEB) and 100×1.49 TIRF objective, and an Andor iXon EMCCD
camera. The Z-stacks were acquired using Fusion software (Andor
Technologies) and the 3D images analyzed using Imaris software
(Bitplane Inc.) creating spots surfaces for the whole image keep-
ing the same conditions for all.
For SDH and PAS analysis, six images per sample were
acquired randomly in places of mixed-intensity fibers keeping
the same light intensity and exposure settings using an Axio
Observer Z1 with ApoTome 2 (Carl Zeiss Ltd.), composed of a
Zeiss 10× ApoPlan objective and an AxioCam ICc1 camera.
Images were acquired using Zen Pro software and analyzed with
Fiji (% of total area) keeping the same threshold for all
samples.
Biochemical analysis of MRC complexes
Brain and skeletal muscle samples were snap-frozen in liquid nitro-
gen and homogenized in 10 mM phosphate buffer (pH 7.4). The
spectrophotometric activity of cI, cII, cIII, and cIV, as well as citrate
synthase (CS), was measured as described in Bugiani et al (2004).
Real-time PCR
RNA was isolated from skeletal muscles using Qiagen RNeasy Kit
according to the manufacturer’s instructions and retrotranscribed
into cDNA using Omniscript Reverse Transcription Kit (Qiagen).
Transcript analysis was carried out by SYBR Green Real-Time PCR,
as described in Viscomi et al (2011). The primers 50-CCTACGAG
ACTGCGAATGGT-30 and 50-CCACAAGAACTGCCATTTTTC-30 were
used to amplify Lamp1.
Western Blot analysis
Mouse tissues were homogenized in ten volumes of 10 mM potas-
sium phosphate buffer (pH 7.4). Mitochondrial-enriched fractions
were collected after centrifugation at 800 g for 10 min in the pres-
ence of protease inhibitors, and frozen and thawed three times in
liquid nitrogen. Protein concentration was determined by the Brad-
ford protein assay (BioRad, Watford, UK). Aliquots, 70 lg each,
were run through a 4–12% SDS–PAGE and electroblotted onto a
nitrocellulose membrane, which was then immunodecorated with
different antibodies.
The paper explained
Problem
Mitochondrial diseases are rare genetic disorders with extreme vari-
ability of symptoms, ranging from relatively benign myopathies to
devastating encephalomyopathies. Mutations in either the nuclear or
mitochondrial DNA can cause defects in the mitochondrial respiratory
chain leading to disease. No cure is currently available for these
conditions.
Results
We tested the efficacy of rapamycin in a mouse model of severe mito-
chondrial myopathy. Rapamycin is an inhibitor of MTORC1, a master
regulator of several cellular pathways, including immune response,
energy metabolism, and autophagy. We found that rapamycin mark-
edly improves the structural and ultrastructural features of our mouse
model by clearing non-functional mitochondria through the coordi-
nated activation of autophagy and lysosomal biogenesis.
Impact
Rapamycin has been shown to be beneficial in a relatively large
number of cellular and animal models of mitochondrial diseases. Our
study suggests a new mechanism of action by rapamycin. These find-
ings warrant future investigation to translate rapamycin or other inhi-
bitors of MTORC1 into the clinical practice.
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Statistical analysis
All numerical data are expressed as mean  standard error of the
mean (SEM). One- or two-way ANOVA with Tukey’s post hoc test
was used for multiple comparisons. Unpaired Student’s t-test was
used for pairwise comparison of independent experimental groups
(see legends). Differences were considered statistically significant
for P < 0.05. Exact P-values and number of animals (n) for each
experiment are in the legends. Power analysis was conducted
assuming a significance level of 0.05 and a probability of detecting
the effect of 80%. Animals were randomized to the different groups
based on the appropriate genotype. No animals were excluded from
analysis. No blinding procedure was used because of the obvious
clinical and morphological phenotypes of the animals the study. We
assumed normal distribution. No particular method was used to
determine whether the data met assumptions of the statistical
approach.
Expanded View for this article is available online.
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